Written by Kate Leaman 
Kate Leaman
Financial Journalist and Market Analyst
Kate Leaman is a seasoned financial analyst and writer with over a decade of experience covering global markets, trading strategies, and macroeconomic trends. She has written for a variety of well-known brokers and has been featured in Forbes, Yahoo Finance, Sky News, The Motley Fool, MSN and Investing.com. using our CLEAR™ Methodology The CLEAR™ Score (Credibility, Leverage, Execution, Accessibility, Regulation) is our proprietary ranking system. The CLEAR™ Score provides you with the most accurate and transparent broker ranking after evaluating all the key factors that are crucial for trading success. .
Last fact check on November 25, 2025 by
Shaun David 
Shaun David
Regulation • Trading Algorithms • Market Analysis
I’m extremely passionate about the financial markets and working with innovative technology that makes trading better and safer. Since joining the CleaRank team, my primary role is working with real-time broker performance data using the CLEAR™ technology and broker evaluation methodology. I investigate brokers by testing their platforms and uncovering hidden risks and costs. My end goal is to level the playing field for traders and With an extensive background in market analysis and algorithmic trading, I’m qualified to find what matters most to traders.
Tempus AI (NASDAQ: TEM): The NVIDIA of Precision Medicine
Key Points
Tempus AI, Inc (NASDAQ: TEM) is a rare combination of a company with major growth potential in an exploding AI sector and a deep personal backstory. We’ll start with the backstory as there’s no better investment than backing what you truly believe in, or finding your so-called “investment purpose” beyond the obvious dollar and cents part of the trade.
Eric Lefkovsky, the CEO and founder of Tempus AI, founded the company in 2015 after searching for a way to save his wife who was diagnosed with breast cancer. He realized that the biggest problem in oncology isn’t a lack of drugs but it’s the lack of personalization. Every tumor behaves differently, and every patient responds differently to the treatment. Two patients might receive the same treatment but the outcomes will vary greatly.
Instead of accepting his wife’s fate, Eric gathered some of the world’s top AI experts and built a platform that connects doctors, computational biology, and decision-making systems to create personalized treatment for every patient.
Growth Explosion & Clinical Data Control
In July 2024, the company went public at a price of $37 per share, and since then it hasn’t stopped its meteoric rise. The explosive growth spurt can be attributed to the continuous and rapid fire announcements of partnerships and FDA approvals. Some of those partners include big pharma such as AstraZeneca and GSK (GlaxoSmithKline)
The real reason why we’re excited about Tempus AI is that they’ve built the largest clinical data library in the world, complete with medical data and operating systems that allow doctors to make decisions and provide personalized treatment to patients. Their algorithms can match precise treatments to each tumor and its unique dynamics. The company’s platform is currently leveraged by 95% of the top 20 pharmaceutical oncology companies.
Think of this data library as the GPU of healthcare. Just as NVIDIA provides the essential infrastructure for computing, Tempus provides the essential data infrastructure required to develop modern drugs. They’re on the fast track to change the face of the entire medical industry as long AI maintains its rapid growth trajectory.
The financial data confirms the ‘breakout’ thesis. Tempus is projected to nearly double its revenue in 2025 while simultaneously crossing the threshold into profitability which is a classic ‘J-Curve’ trajectory seen in successful platform stocks.
Tempus AI Financial Performance
Annual revenue growth and path to profitability (Adjusted EBITDA).
| Year | Annual Revenue | YoY Growth | Adj. EBITDA |
|---|---|---|---|
| 2023 | $531.8M | 66% | $(133.3)M |
| 2024 | $693.4M | 30.4% | $(104.7)M |
| 2025 (Guidance) | ~$1,240.0M | ~79% | +$5.0M |
Key Pivot: 2025 Guidance suggests a pivotal year for Tempus AI, with near-doubling revenue growth (~79%) and the first positive Adjusted EBITDA milestone.
Historic Collaboration with the U.S. government
Undoubtedly the most pivotal announcement thus far for Tempus AI was its selection to provide services and data infrastructure for ARPA-H, the advanced research agency of the U.S. Department of Health and Human Services. The program is called ADAPT, and its goal is to revolutionize cancer treatment by developing therapeutic strategies that use biological markers (biomarkers) to target metastatic disease at its earliest stages.
The program is currently focused on lung cancer, breast cancer, and colorectal cancer, and its ultimate goal is to improve patient survival rates. Tumors evolve during treatment and develop resistance. This makes it difficult for doctors to determine the next step of therapy, and the ADAPT program is designed to tackle exactly this challenge.
Tempus plays a central role in the program. It uses its AI-based diagnostic platform, manages the clinical trials, and leverages its expertise in data collection and research analysis. Tempus will accelerate the development of personalized treatments that respond in real time to tumor evolution.
“Tempus AI is creating medicine that is alive, adaptive, and continuously updating. This is a project which is saving lives and improving survival rates. We expect demand growth to be linear.”
Jacob Bakshi, Senior Market Strategist at CleaRank, explained the buzz
The Case for Tempus AI: Massive Upside, Real Risks
It’s not just Jacob Bakshi that is excited about Tempus AI. The overwhelming consensus among the CleaRank analysts is that they’re on the fast track to become part of one of the major tech giants or to be acquired by one.
The reasons for their optimism are hard to dispute:
The World's Largest Precision Medicine Library
Tempus AI has aggregated one of the largest multimodal medical datasets on Earth.
Record Volume Breakdown
* Note: Chart uses a logarithmic scale due to the massive difference in volume between total records and sub-categories.
Tempus is one of the most ambitious AI-health platforms in the world, but with that ambition comes high execution risk.
Jacob Bakshi, weighed in on the risk side:
“They have the potential to become the “NVIDIA of precision medicine”. But their numerous challenges could slow down or, in the worst case, limit their ability to scale.”
Before we lead in with our price prediction for TEM, it's important to fully digest the risks:
Tempus AI Inc. (TEM) Price Prediction Based on CleaRank 4-Year Model
Based on:
Tempus AI ($TEM) Price Target Forecast
4-Year projection scenarios (2025–2029) across Bear, Base, and Bull cases.
| Year | Bear Case Target | Base Case Target | Bull Case Target |
|---|---|---|---|
| 2025 | $95 – $110 | $130 – $150 | $170 – $190 |
| 2026 | $120 – $140 | $180 – $220 | $260 – $300 |
| 2027 | $140 – $170 | $230 – $300 | $330 – $420 |
| 2028 | $160 – $200 | $300 – $380 | $420 – $520+ |
| 2029 (Stretch) | $180 – $230 | $360 – $450 | $500 – $650+ |
Scenario Reasoning
Bear Case: “Execution Drag”
Base Case: “Precision OS Takes Hold”
Bull Case : “Precision Medicine Leader”
“Tempus AI is a rare healthcare company with true data moat, exponential AI leverage, and a clear pathway to become the operating system of precision medicine. If the bull case plays out, Tempus could follow a trajectory similar to early NVIDIA but in healthcare instead of GPUs.”
Jacob Bakshi, underpinned this bullish perspective
FAQ
Disclaimer & Investment Risk The content provided in this article, including the CleaRank price forecasts and analysis of Tempus AI (TEM), is for informational and educational purposes only and should not be construed as professional financial advice, investment recommendations, or an offer to buy or sell any securities. The "Base Case" and "Bull Case" scenarios are hypothetical projections based on current market data and assumptions that may not materialize.
Investing in high-growth sectors like Artificial Intelligence and Precision Medicine involves a high degree of risk, including the potential loss of principal. Stock prices can be highly volatile. "CleaRank" and its analysts are not registered investment advisors. Readers are strongly encouraged to conduct their own due diligence and consult with a certified financial planner or tax professional before making any investment decisions. The author or CleaRank may hold positions in the securities mentioned.
Kate Leaman
Kate Leaman is a seasoned financial analyst and writer with over a decade of experience covering global markets, trading strategies, and macroeconomic trends. She has written for a variety of well-known brokers and has been featured in Forbes, Yahoo Finance, Sky News, The Motley Fool, MSN and Investing.com.
Kate provides expert commentary on forex, equities, and commodities, blending analytical precision with accessible storytelling. Her work bridges institutional research and retail investor education, helping readers navigate market volatility and understand the forces shaping investor sentiment.
Recognised for her clear insights and grounded approach, Kate brings a sharp, data-driven perspective to everything from central bank policy to emerging trends in the global economy.
